関連する実験動画
Updated: Sep 9, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.0K
重度の喘息に対するテゼペルマブの実用的な証拠: 遡及的な多センターコホート
Jasmin Khateeb1,2,3, Mordechai R Kramer4,5, Ophir Freund5,6
1Pulmonary Institute, Rambam Health Care Campus, Haifa, Israel.
ERJ open research
|September 3, 2025
まとめ
実際のデータによると,テゼペルマブは重度の喘息患者における悪化とコルチコステロイドの使用を著しく減少させた. 低エオシノフィルの患者でも この生物学的治療は肺機能と症状の負担を改善しました
科学分野:
- 免疫学
- 肺科
- 薬理学について
背景:
- テゼペルマブは 胸膜のリンパポエチン阻害剤で 重度の喘息の治療に 有望な効果を示しています
- 様々な重度の喘息患者におけるテゼペルマブの有効性に関する実際のデータは限られている.
- テゼペルマブの臨床的有用性を理解するには,実際の結果の評価が不可欠です.
研究 の 目的:
- テゼペルマブを投与開始した重度の喘息患者の実際の特徴と治療結果を評価する.
- 発症率,肺機能,コルチコステロイド使用に対するテゼペルマブの影響を分析する.
主な方法:
- テゼペルマブで治療された103人の成人重度の喘息患者を対象とした多センターコホート研究.
- 発症,肺機能 (FEV1),および初期および1年間のフォローアップにおけるコルチコステロイド使用に関するデータ
- 分析には,以前の生物学的使用とエオシノフィルの数に基づいたサブグループ評価が含まれていました.
主要な成果:
- 毎年発生する喘息の相対的な減少が観察されました.
- 1秒間の強制排気量 (FEV1) の有意な改善が認められた.
- 45%の患者は維持用経口用コルチコステロイドの投与を中止し,23%は投与量を50%以上減らしました.
結論:
- テゼペルマブによる実際の治療は,喘息のコントロールを改善し,悪化とコルチコステロイド依存を軽減しました.
- 生物学的経験のある患者と低エオシノフィルの患者のサブグループでは,利益は一貫していました.
- テゼペルマブは,重度の喘息の管理に有効であることが,日常的な臨床試験で示されました.
関連する概念動画
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:24Asthma-III: Symptoms and Complications
2.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.6K
01:20Asthma: Pathogenesis and Management
576
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
576
01:26Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
01:29Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
01:19Antiasthma Drugs: Leukotriene Modifiers
461
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
461